Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy Virtual 2020 | The impact of COVID-19 on clinical practice

Irene Ghobrial • 28 Apr 2020
COMy Virtual 2020
Multiple Myeloma Rare Diseases Smoldering Myeloma

Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, delineates how the COVID-19 pandemic has impacted cancer care. The benefit of telemedicine, the speed at which clinical trials are being opened as well as the interaction between myeloma, MGUS, and smoldering myeloma with COVID-19 is also discussed. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Irene Ghobrial

0:52
Using spatial proteomics to analyze the bone marrow microenvironment in SMM treated with nivolumab
Irene Ghobrial • 7 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
Early interception in SMM & novel agents being explored
Irene Ghobrial et al. • 25 Mar 2024
1:19
Single-cell sequencing of circulating tumor cells to predict progression from MGUS/SMM
Irene Ghobrial • 11 Dec 2023

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals